BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

233 related articles for article (PubMed ID: 36250099)

  • 1. Using Clustered Regularly Interspaced Short Palindromic Repeats gene editing to induce permanent expression of fetal hemoglobin in β-thalassemia and sickle cell disease: A comparative meta-analysis.
    Quagliano A; Acevedo D; Hardigan P; Prasad S
    Front Med (Lausanne); 2022; 9():943631. PubMed ID: 36250099
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome editing of HBG1 and HBG2 to induce fetal hemoglobin.
    Métais JY; Doerfler PA; Mayuranathan T; Bauer DE; Fowler SC; Hsieh MM; Katta V; Keriwala S; Lazzarotto CR; Luk K; Neel MD; Perry SS; Peters ST; Porter SN; Ryu BY; Sharma A; Shea D; Tisdale JF; Uchida N; Wolfe SA; Woodard KJ; Wu Y; Yao Y; Zeng J; Pruett-Miller S; Tsai SQ; Weiss MJ
    Blood Adv; 2019 Nov; 3(21):3379-3392. PubMed ID: 31698466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Precision Editing as a Therapeutic Approach for β-Hemoglobinopathies.
    Paschoudi K; Yannaki E; Psatha N
    Int J Mol Sci; 2023 May; 24(11):. PubMed ID: 37298481
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Targeted deletion of BCL11A gene by CRISPR-Cas9 system for fetal hemoglobin reactivation: A promising approach for gene therapy of beta thalassemia disease.
    Khosravi MA; Abbasalipour M; Concordet JP; Berg JV; Zeinali S; Arashkia A; Azadmanesh K; Buch T; Karimipoor M
    Eur J Pharmacol; 2019 Jul; 854():398-405. PubMed ID: 31039344
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative targeting analysis of KLF1, BCL11A, and HBG1/2 in CD34
    Lamsfus-Calle A; Daniel-Moreno A; Antony JS; Epting T; Heumos L; Baskaran P; Admard J; Casadei N; Latifi N; Siegmund DM; Kormann MSD; Handgretinger R; Mezger M
    Sci Rep; 2020 Jun; 10(1):10133. PubMed ID: 32576837
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CRISPR-Cas9 Editing of the
    Sharma A; Boelens JJ; Cancio M; Hankins JS; Bhad P; Azizy M; Lewandowski A; Zhao X; Chitnis S; Peddinti R; Zheng Y; Kapoor N; Ciceri F; Maclachlan T; Yang Y; Liu Y; Yuan J; Naumann U; Yu VWC; Stevenson SC; De Vita S; LaBelle JL
    N Engl J Med; 2023 Aug; 389(9):820-832. PubMed ID: 37646679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of novel HPFH-like mutations by CRISPR base editing that elevate the expression of fetal hemoglobin.
    Ravi NS; Wienert B; Wyman SK; Bell HW; George A; Mahalingam G; Vu JT; Prasad K; Bandlamudi BP; Devaraju N; Rajendiran V; Syedbasha N; Pai AA; Nakamura Y; Kurita R; Narayanasamy M; Balasubramanian P; Thangavel S; Marepally S; Velayudhan SR; Srivastava A; DeWitt MA; Crossley M; Corn JE; Mohankumar KM
    Elife; 2022 Feb; 11():. PubMed ID: 35147495
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Induction of fetal hemoglobin synthesis by CRISPR/Cas9-mediated editing of the human β-globin locus.
    Antoniani C; Meneghini V; Lattanzi A; Felix T; Romano O; Magrin E; Weber L; Pavani G; El Hoss S; Kurita R; Nakamura Y; Cradick TJ; Lundberg AS; Porteus M; Amendola M; El Nemer W; Cavazzana M; Mavilio F; Miccio A
    Blood; 2018 Apr; 131(17):1960-1973. PubMed ID: 29519807
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined approaches for increasing fetal hemoglobin (HbF) and
    Finotti A; Gambari R
    Front Genome Ed; 2023; 5():1204536. PubMed ID: 37529398
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The Novel Role of the B-Cell Lymphoma/Leukemia 11A (BCL11A) Gene in β-Thalassaemia Treatment.
    Mahmoud Ahmed NH; Lai MI
    Cardiovasc Hematol Disord Drug Targets; 2023; 22(4):226-236. PubMed ID: 36734897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. CRISPR/Cas9 Ablated BCL11A Unveils the Genes with Possible Role of Globin Switching.
    Movahedi Motlagh F; Soleimanpour-Lichaei HR; Shamsara M; Etemadzadeh A; Modarressi MH
    Adv Pharm Bull; 2023 Nov; 13(4):799-805. PubMed ID: 38022811
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Base editing of key residues in the BCL11A-XL-specific zinc finger domains derepresses fetal globin expression.
    Rajendiran V; Devaraju N; Haddad M; Ravi NS; Panigrahi L; Paul J; Gopalakrishnan C; Wyman S; Ariudainambi K; Mahalingam G; Periyasami Y; Prasad K; George A; Sukumaran D; Gopinathan S; Pai AA; Nakamura Y; Balasubramanian P; Ramalingam R; Thangavel S; Velayudhan SR; Corn JE; Mackay JP; Marepally S; Srivastava A; Crossley M; Mohankumar KM
    Mol Ther; 2024 Mar; 32(3):663-677. PubMed ID: 38273654
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CRISPR-Cas9 to induce fetal hemoglobin for the treatment of sickle cell disease.
    Demirci S; Leonard A; Essawi K; Tisdale JF
    Mol Ther Methods Clin Dev; 2021 Dec; 23():276-285. PubMed ID: 34729375
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeting fetal hemoglobin expression to treat β hemoglobinopathies.
    Steinberg MH
    Expert Opin Ther Targets; 2022 Apr; 26(4):347-359. PubMed ID: 35418266
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Induction of Fetal Hemoglobin by Introducing Natural Hereditary Persistence of Fetal Hemoglobin Mutations in the γ-Globin Gene Promoters for Genome Editing Therapies for β-Thalassemia.
    Lu D; Xu Z; Peng Z; Yang Y; Song B; Xiong Z; Ma Z; Guan H; Chen B; Nakamura Y; Zeng J; Liu N; Sun X; Chen D
    Front Genet; 2022; 13():881937. PubMed ID: 35656314
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct Promoter Repression by BCL11A Controls the Fetal to Adult Hemoglobin Switch.
    Liu N; Hargreaves VV; Zhu Q; Kurland JV; Hong J; Kim W; Sher F; Macias-Trevino C; Rogers JM; Kurita R; Nakamura Y; Yuan GC; Bauer DE; Xu J; Bulyk ML; Orkin SH
    Cell; 2018 Apr; 173(2):430-442.e17. PubMed ID: 29606353
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CRISPR/Cas-based gene editing in therapeutic strategies for beta-thalassemia.
    Zeng S; Lei S; Qu C; Wang Y; Teng S; Huang P
    Hum Genet; 2023 Dec; 142(12):1677-1703. PubMed ID: 37878144
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Negative regulation of
    Jia W; Wu X; Chen Z; Lin W; He Y
    Transl Pediatr; 2023 May; 12(5):907-917. PubMed ID: 37305725
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical genome editing to treat sickle cell disease-A brief update.
    Zarghamian P; Klermund J; Cathomen T
    Front Med (Lausanne); 2022; 9():1065377. PubMed ID: 36698803
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Epigenetic inactivation of ERF reactivates γ-globin expression in β-thalassemia.
    Bao X; Zhang X; Wang L; Wang Z; Huang J; Zhang Q; Ye Y; Liu Y; Chen D; Zuo Y; Liu Q; Xu P; Huang B; Fang J; Lao J; Feng X; Li Y; Kurita R; Nakamura Y; Yu W; Ju C; Huang C; Mohandas N; Li D; Zhao C; Xu X
    Am J Hum Genet; 2021 Apr; 108(4):709-721. PubMed ID: 33735615
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.